Treatment of Chronic Granulocytic Leukemia with Myleran
- 18 April 1957
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 256 (16) , 727-734
- https://doi.org/10.1056/nejm195704182561602
Abstract
THE chemotherapeutic agent Myleran has been under investigation for the treatment of leukemia during the past five years. This compound, 1:4 - dimethanesulfonyloxybutane (CH3SO2OCH2CH2CH2CH2OSO2CH3), which was synthesized by Timmis1 in 1950, had an intense inhibitory effect on the growth of the Walker rat carcinoma 256 as well as a depressive influence on the myeloid series both in the rat and in man. Haddow and Timmis1 showed that the main depressant action of Myleran was on circulating neutrophils in rats. This led to its trial . . .Keywords
This publication has 10 references indexed in Scilit:
- CHEMOTHERAPY OF LEUKEMIA, HODGKIN'S DISEASE AND RELATED DISORDERSAnnals of Internal Medicine, 1954
- The effect of 1,4-dimethanesulfonyloxybutane (GT-41 or myleran) upon leukemiaCancer, 1954
- The Outlook for the Eventual Control of LeukemiaNew England Journal of Medicine, 1954
- Clinical Evaluation of a New Antimetabolite, 6-Mercaptopurine, in the Treatment of Leukemia and Allied DiseasesBlood, 1953
- TREATMENT OF CHRONIC LEUKEMIASJAMA, 1952
- Radioactive phosphorus. II. In the treatment of myeloid leukemiaCancer, 1951
- THE THERAPEUTIC APPLICATION OF RADIOACTIVE PHOSPHORUS WITH SPECIAL REFERENCE TO THE TREATMENT OF PRIMARY POLYCYTHEMIA AND CHRONIC MYELOID LEUKEMIA 1Journal of Clinical Investigation, 1949
- THE USE OF URETHANE (ETHYL CARBAMATE) IN THE TREATMENT OF LEUKEMIABlood, 1948
- RADIOACTIVE PHOSPHORUS AS A THERAPEUTIC AGENT - A REVIEW OF THE LITERATURE AND ANALYSIS OF THE RESULTS OF TREATMENT OF 155 PATIENTS WITH VARIOUS BLOOD DYSCRASIAS, LYMPHOMAS, AND OTHER MALIGNANT NEOPLASTIC DISEASES1946